Menlo Park, CA, United States of America

Zili An

This inventor holds 2 USPTO granted patents. Top assignee: Adicet Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zili An. Retrieved from https://idiyas.com/inventor/zili-an-r8fb43f8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Zili An and His Patent Work in Cellular Immunotherapy.

Introduction

Zili An is an inventor based in Menlo Park, California, whose listed patent work concerns gamma delta T-cell approaches to treating cancer. He is associated with Adicet Therapeutics, Inc. His record includes 2 patents.

Latest Patents

The supplied patent titles describe compositions and methods involving engineered and non-engineered gamma delta T cells for treating solid tumors and hematological tumors. Together, they focus on potential cellular immunotherapy applications across two broad categories of cancer.

Career Highlights

An’s listed work connects his inventorship with research and development at Adicet Therapeutics, a company working in the biotechnology field. The available information identifies his location and patent portfolio but does not provide further details about his education or career history.

Collaborations

Marissa Ann Herrman and Jason Michael Romero are identified as An’s coworkers. Their names appear alongside his work on gamma delta T-cell compositions and methods.

Conclusion

Zili An’s patent record highlights work on gamma delta T-cell approaches for solid and hematological tumors, reflecting his association with Adicet Therapeutics and its biotechnology research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…